MDxHealth SA ADR
$ 2.27
6.07%
14 Apr - close price
- Market Cap 109,920,000 USD
- Current Price $ 2.27
- High / Low $ 2.34 / 2.16
- Stock P/E N/A
- Book Value -0.23
- EPS -0.67
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -24.40 %
- 52 Week High 5.33
- 52 Week Low 1.51
About
MDxHealth SA is a pioneering biotechnology company focused on precision diagnostics that enhance cancer management, particularly for prostate and bladder cancers. The company has developed and commercialized advanced diagnostic solutions, including its flagship product, ConfirmMDx for Prostate Cancer, which is recognized for its clinical efficacy and strong market presence. As the field of personalized medicine advances and the need for targeted cancer therapies rises, MDxHealth is well-positioned to expand its innovative offerings and address significant unmet needs in oncology, ultimately aiming to improve patient outcomes and drive growth.
Analyst Target Price
$7.40
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-26 | 2025-11-12 | 2025-08-14 | 2025-05-14 | 2025-02-26 | 2024-11-06 | 2024-08-21 | 2024-05-01 | 2024-03-06 | 2023-11-08 | 2023-08-23 | 2023-05-15 |
| Reported EPS | -0.17 | -0.16 | -0.14 | -0.19 | -0.14 | -0.4 | -0.42 | -0.31 | -0.39 | -0.4 | -0.3 | -0.5 |
| Estimated EPS | -0.1251 | -0.17 | -0.12 | -0.13 | -0.19 | -0.25 | -0.26 | -0.3 | -0.11 | -0.19 | -0.22 | -0.5 |
| Surprise | -0.0449 | 0.01 | -0.02 | -0.06 | 0.05 | -0.15 | -0.16 | -0.01 | -0.28 | -0.21 | -0.08 | 0 |
| Surprise Percentage | -35.8913% | 5.8824% | -16.6667% | -46.1538% | 26.3158% | -60% | -61.5385% | -3.3333% | -254.5455% | -110.5263% | -36.3636% | 0% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.13 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MDXH
2026-04-13 19:39:49
MDxHealth's Chief Commercial Officer, John Bellano, has disclosed an initial statement of beneficial ownership detailing multiple share option awards. These grants span from June 2019 to March 2025, with varying exercise prices, expiration dates, and vesting schedules tied to both time-based installments and company performance criteria. The filing indicates that Bellano directly holds these options, which are not current share trades.
2026-04-13 19:39:49
An MDxHealth SA officer, Joseph Sollee, has filed an initial Form 3 detailing his holdings of share options. The filing outlines numerous option grants with varied exercise prices in both euros and U.S. dollars, distinct vesting schedules, some of which are performance-based, and expiration dates extending as far as 2035. This disclosure provides insight into Sollee's extensive equity incentives with MDxHealth.
2026-04-13 19:39:49
This article details an initial statement of beneficial ownership (Form 3) filed by Ron Kalfus, CFO of MDxHealth SA (MDXH). The filing outlines his holdings of share options, with various strike prices in Euros and USD, and expiration dates ranging from 2029 to 2035. These options generally vest in three equal annual installments or upon achieving specific company performance criteria.
2026-04-13 13:39:49
Short interest in MDxHealth SA (NASDAQ:MDXH) rose significantly by 88.5% in March, indicating increased investor skepticism about the company's near-term performance. The number of shares sold short reached 73,632, representing 0.2% of total shares outstanding, with a short interest ratio of 0.3 days based on current trading volume. This surge suggests potential downward pressure on the stock price and highlights the need for close monitoring by analysts.
2026-04-11 02:39:07
Don M. Hardison, a director at MDxHealth SA (MDXH), has reported initial holdings of 40,000 company share options. These options are divided into two grants: 30,000 ordinary shares at an exercise price of $2.62, granted on June 22, 2024, and 10,000 ordinary shares at $2.18, granted on June 27, 2025, both vesting in full at subsequent annual general shareholders' meetings. The filing is an initial statement of beneficial ownership and does not indicate any open-market buying or selling activity.
2026-04-09 20:09:29
An MDxHealth SA director, Hilde Windels, has filed an initial ownership report detailing her indirect holdings of share options in MDxHealth SA through Hilde Windels BV. The report lists significant option grants from prior years with varying exercise prices and expiration dates, summing up to 42,000 ordinary shares. Although the options are held by Hilde Windels BV, they are deemed beneficially owned by Ms. Windels as the managing director, though she disclaims beneficial ownership except for any pecuniary interest.
